Navigation Links
Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome
Date:12/5/2007

or the placebo group, explained Dr. Falutz. Also, the side-effects are minimal.

"This is a novel strategy to improve cardiovascular risk indices in HIV-infected patients and could represent a therapeutic breakthrough for many patients", stated Dr. Grinspoon.

A second confirmatory trial is ongoing in order to comply with US FDA (US Food and Drug Administration) regulations. If this second clinical study is as conclusive as the first, there is hope that patients will have tesamorelin available as a treatment option for HIV-associated lipodystrophy within the next couple of years., said Dr. Falutz.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CVS Joins Retail Push for Non-Toxic Personal Care Products 2Health News:CVS Joins Retail Push for Non-Toxic Personal Care Products 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:AIDS.gov Goes 2.0: Government HIV/AIDS Website Now Features a Blog, Podcasts, and More 2Health News:Hunger Hormone Makes Food Look More Tasty 2Health News:Hunger Hormone Makes Food Look More Tasty 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 2Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 3Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 4Health News:Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008 5
Breaking Medicine Technology:AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Negative Pressure Wound Devices Draw FDA Notice, Advice 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Photo 3A Poor Disabled Children in Ecuador Receive Free Wheelchairs 21 56135 1Photo 3A Poor Disabled Children in Ecuador Receive Free Wheelchairs 21 56135 2Photo 3A Poor Disabled Children in Ecuador Receive Free Wheelchairs 21 56135 3Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility 56131 1Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility 56131 2Regado Biosciences to Present at the Rodman 26 Renshaw Global Investment Conference on September 10 2009 13829 1Regado Biosciences to Present at the Rodman 26 Renshaw Global Investment Conference on September 10 2009 13829 2
Other Medicine Technology:Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 2OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 3OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 4